Cathie Wood’s ARK Invest Shifts Focus: Trims Tempus AI, Boosts Arcturus Therapeutics
ARK Invest, led by Cathie Wood, executed significant portfolio adjustments on September 15, 2025, reducing exposure to Tempus AI while increasing its stake in Arcturus Therapeutics. The ARK Genomic Revolution ETF sold 7,270 shares of Tempus AI, valued at approximately $627,982, continuing a trend of gradual divestment from the AI healthcare firm.
Tempus AI, which leverages artificial intelligence to enhance clinical decision-making, retains a Moderate Buy rating among analysts. The average price target of $75.09 suggests cautious Optimism despite ARK's sell-off. Meanwhile, the fund's growing position in Arcturus Therapeutics signals renewed confidence in biotech innovation.